Long-term results and pharmacokinetics of high-dose paclitaxel in patients with refractory epithelial ovarian carcinoma
- 1 January 1999
- journal article
- research article
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 9 (1) , 44-53
- https://doi.org/10.1046/j.1525-1438.1999.09856.x
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Clinical Pharmacokinetics of PaclitaxelClinical Pharmacokinetics, 1994
- Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.Journal of Clinical Oncology, 1994
- Dose-Intense Taxol: High Response Rate in Patients With Platinum-Resistant Recurrent Ovarian CancerJNCI Journal of the National Cancer Institute, 1994
- Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.Journal of Clinical Oncology, 1993
- High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol®) in human plasmaJournal of Chromatography B: Biomedical Sciences and Applications, 1993
- Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations.Proceedings of the National Academy of Sciences, 1993
- Management of Pharmacokinetic Data Using HP-3357/Mainframe Ibm InterfacingDrug Information Journal, 1987
- Measuring the quality of life of cancer patientsJournal of Chronic Diseases, 1981
- The application of statistical moment theory to the evaluation ofin vivo dissolution time and absorption timeJournal of Pharmacokinetics and Biopharmaceutics, 1980
- Intensive Surgical and Chemotherapeutic Management of Advanced Ovarian CancerSurgical Clinics of North America, 1978